BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 18398105)

  • 1. Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial.
    Rohan TE; Negassa A; Chlebowski RT; Habel L; McTiernan A; Ginsberg M; Wassertheil-Smoller S; Page DL
    J Natl Cancer Inst; 2008 Apr; 100(8):563-71. PubMed ID: 18398105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re: Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial.
    Wood C; Cline M
    J Natl Cancer Inst; 2008 Sep; 100(18):1335; author reply 1335-6. PubMed ID: 18780867
    [No Abstract]   [Full Text] [Related]  

  • 3. Menstrual and reproductive history, postmenopausal hormone use, and risk of benign proliferative epithelial disorders of the breast: a cohort study.
    Cui Y; Page DL; Lane DS; Rohan TE
    Breast Cancer Res Treat; 2009 Mar; 114(1):113-20. PubMed ID: 18360772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
    McTiernan A; Martin CF; Peck JD; Aragaki AK; Chlebowski RT; Pisano ED; Wang CY; Brunner RL; Johnson KC; Manson JE; Lewis CE; Kotchen JM; Hulka BS;
    J Natl Cancer Inst; 2005 Sep; 97(18):1366-76. PubMed ID: 16174858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.
    Anderson GL; Chlebowski RT; Rossouw JE; Rodabough RJ; McTiernan A; Margolis KL; Aggerwal A; David Curb J; Hendrix SL; Allan Hubbell F; Khandekar J; Lane DS; Lasser N; Lopez AM; Potter J; Ritenbaugh C
    Maturitas; 2006 Sep; 55(2):103-15. PubMed ID: 16815651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results.
    Kuhl H; Stevenson J
    Gynecol Endocrinol; 2006 Jun; 22(6):303-17. PubMed ID: 16785155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen plus progestin and risk of benign proliferative breast disease.
    Rohan TE; Negassa A; Chlebowski RT; Lasser NL; McTiernan A; Schenken RS; Ginsberg M; Wassertheil-Smoller S; Page DL
    Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2337-43. PubMed ID: 18725513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative.
    Hendrix SL; Wassertheil-Smoller S; Johnson KC; Howard BV; Kooperberg C; Rossouw JE; Trevisan M; Aragaki A; Baird AE; Bray PF; Buring JE; Criqui MH; Herrington D; Lynch JK; Rapp SR; Torner J;
    Circulation; 2006 May; 113(20):2425-34. PubMed ID: 16702472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conjugated equine estrogens and peripheral arterial disease risk: the Women's Health Initiative.
    Hsia J; Criqui MH; Herrington DM; Manson JE; Wu L; Heckbert SR; Allison M; McDermott MM; Robinson J; Masaki K;
    Am Heart J; 2006 Jul; 152(1):170-6. PubMed ID: 16824852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative.
    Hsia J; Langer RD; Manson JE; Kuller L; Johnson KC; Hendrix SL; Pettinger M; Heckbert SR; Greep N; Crawford S; Eaton CB; Kostis JB; Caralis P; Prentice R;
    Arch Intern Med; 2006 Feb; 166(3):357-65. PubMed ID: 16476878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venous thrombosis and conjugated equine estrogen in women without a uterus.
    Curb JD; Prentice RL; Bray PF; Langer RD; Van Horn L; Barnabei VM; Bloch MJ; Cyr MG; Gass M; Lepine L; Rodabough RJ; Sidney S; Uwaifo GI; Rosendaal FR
    Arch Intern Med; 2006 Apr; 166(7):772-80. PubMed ID: 16606815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial.
    Jackson RD; Wactawski-Wende J; LaCroix AZ; Pettinger M; Yood RA; Watts NB; Robbins JA; Lewis CE; Beresford SA; Ko MG; Naughton MJ; Satterfield S; Bassford T;
    J Bone Miner Res; 2006 Jun; 21(6):817-28. PubMed ID: 16753012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors.
    Holmberg L; Iversen OE; Rudenstam CM; Hammar M; Kumpulainen E; Jaskiewicz J; Jassem J; Dobaczewska D; Fjosne HE; Peralta O; Arriagada R; Holmqvist M; Maenpaa J;
    J Natl Cancer Inst; 2008 Apr; 100(7):475-82. PubMed ID: 18364505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.
    Anderson GL; Limacher M; Assaf AR; Bassford T; Beresford SA; Black H; Bonds D; Brunner R; Brzyski R; Caan B; Chlebowski R; Curb D; Gass M; Hays J; Heiss G; Hendrix S; Howard BV; Hsia J; Hubbell A; Jackson R; Johnson KC; Judd H; Kotchen JM; Kuller L; LaCroix AZ; Lane D; Langer RD; Lasser N; Lewis CE; Manson J; Margolis K; Ockene J; O'Sullivan MJ; Phillips L; Prentice RL; Ritenbaugh C; Robbins J; Rossouw JE; Sarto G; Stefanick ML; Van Horn L; Wactawski-Wende J; Wallace R; Wassertheil-Smoller S;
    JAMA; 2004 Apr; 291(14):1701-12. PubMed ID: 15082697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.
    Shumaker SA; Legault C; Kuller L; Rapp SR; Thal L; Lane DS; Fillit H; Stefanick ML; Hendrix SL; Lewis CE; Masaki K; Coker LH;
    JAMA; 2004 Jun; 291(24):2947-58. PubMed ID: 15213206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cigarette smoking and risk of benign proliferative epithelial disorders of the breast in the Women's Health Initiative.
    Cui Y; Page DL; Chlebowski RT; Hsia J; Allan Hubbell F; Johnson KC; Rohan TE
    Cancer Causes Control; 2007 May; 18(4):431-8. PubMed ID: 17323143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.
    Prescrire Int; 2004 Jun; 13(71):106-9. PubMed ID: 15233153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types.
    Marshall LM; Hunter DJ; Connolly JL; Schnitt SJ; Byrne C; London SJ; Colditz GA
    Cancer Epidemiol Biomarkers Prev; 1997 May; 6(5):297-301. PubMed ID: 9149887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of oral conjugated estrogen alone and risk of breast cancer.
    Zhang SM; Manson JE; Rexrode KM; Cook NR; Buring JE; Lee IM
    Am J Epidemiol; 2007 Mar; 165(5):524-9. PubMed ID: 17132697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.
    Modena MG; Sismondi P; Mueck AO; Kuttenn F; Lignières Bd; Verhaeghe J; Foidart JM; Caufriez A; Genazzani AR;
    Maturitas; 2005 Sep; 52(1):1-10. PubMed ID: 15963666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.